Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. My name is Jim, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amelix Pharmaceuticals fourth quarter and full year 2025 earnings conference call. All participants will be in a listen-only mode, and after today's presentation, there will be the opportunity to ask questions. To place yourself into a queue, please press star and one on your telephone keypad. To withdraw your question, you can repeat the steps of star and one. Please limit yourself to one question with one follow-up today, and if you have additional questions, you are invited to rejoin the queue. Please be advised that this call is being recorded at the company's request, and it is now my pleasure to turn the floor over to Lindsay Allen, Vice President, Investor Relations and Communications. Welcome, Lindsay. Good morning, and thank you all for joining us today to discuss our fourth quarter and full year 2025 financial results and business updates. With me on the call today are Josh Cohen and Justin Klee, our co-CEOs, Dr. Camille Bedrosian, our chief medical officer, and Jim Fradies, our chief financial officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans, and expectations and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to Avexatide, AMX 35, AMX 114, and AMX 318, statements regarding regulatory and clinical developments, the impact thereof and the expected timing thereof, and statements regarding our cash runway. Act...